CA3128097C - Anticorps anti-cd228 et conjugues anticorps-medicament - Google Patents

Anticorps anti-cd228 et conjugues anticorps-medicament

Info

Publication number
CA3128097C
CA3128097C CA3128097A CA3128097A CA3128097C CA 3128097 C CA3128097 C CA 3128097C CA 3128097 A CA3128097 A CA 3128097A CA 3128097 A CA3128097 A CA 3128097A CA 3128097 C CA3128097 C CA 3128097C
Authority
CA
Canada
Prior art keywords
antibody
cancer
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3128097A
Other languages
English (en)
Other versions
CA3128097A1 (fr
Inventor
Sharsti SANDALL
Lori Westendorf
Timothy Lewis
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Priority claimed from PCT/US2020/016381 external-priority patent/WO2020163225A1/fr
Publication of CA3128097A1 publication Critical patent/CA3128097A1/fr
Application granted granted Critical
Publication of CA3128097C publication Critical patent/CA3128097C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne de nouveaux anticorps anti-CD228 et des conjugués anticorps-médicament ainsi que des procédés d'utilisation de tels anticorps anti-CD228 et de conjugués anticorps-médicament dans le traitement du cancer.
CA3128097A 2019-02-05 2020-02-03 Anticorps anti-cd228 et conjugues anticorps-medicament Active CA3128097C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962801590P 2019-02-05 2019-02-05
US62/801,590 2019-02-05
US201962824923P 2019-03-27 2019-03-27
US62/824,923 2019-03-27
US201962879660P 2019-07-29 2019-07-29
US62/879,660 2019-07-29
US201962882016P 2019-08-02 2019-08-02
US62/882,016 2019-08-02
US201962934424P 2019-11-12 2019-11-12
US62/934,424 2019-11-12
PCT/US2020/016381 WO2020163225A1 (fr) 2019-02-05 2020-02-03 Anticorps anti-cd228 et conjugués anticorps-médicament

Publications (2)

Publication Number Publication Date
CA3128097A1 CA3128097A1 (fr) 2020-08-13
CA3128097C true CA3128097C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
US20240409658A1 (en) Anti-cd228 antibodies and antibody-drug conjugates
TWI883057B (zh) 抗pd-l1抗體及抗體藥物結合物
US12268751B2 (en) Anti-αVβ6 antibodies and antibody-drug conjugates
US20230295330A1 (en) Anti-cd228 antibodies and antibody-drug conjugates
CA3128097C (fr) Anticorps anti-cd228 et conjugues anticorps-medicament
CN114828887B (zh) 抗-αVβ6抗体和抗体-药物偶联物
EA050557B1 (ru) Анти-cd228 антитела и конъюгаты антитело-лекарственное средство
HK40064761A (en) Anti-cd228 antibodies and antibody-drug conjugates
JP2025537099A (ja) 抗αＶβ６抗体および抗体－薬物コンジュゲートならびにがんの治療におけるそれらの使用
HK40064761B (zh) 抗cd228抗体和抗体-药物缀合物
EA052759B1 (ru) Антитела против pd-l1 и конъюгаты антитело-лекарственное средство